Estrella Immunopharma Inc. (ESLAW)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Estrella Immunopharma Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Estrella Immunopharma Inc. (ESLAW) has returned 49.80% so far this year and -2.85% over the past 12 months.

Based on dividend-adjusted daily data since Sep 14, 2021, ESLAW's average daily return is +1.66%, while the average monthly return is +7.44%. At this rate, your investment would double in approximately 0.8 years.

Historically, 53% of months were positive and 47% were negative. The best month was Jul 2023 with a return of +188.3%, while the worst month was Sep 2022 at -68.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.

On a daily basis, ESLAW closed higher 20% of trading days. The best single day was Nov 25, 2022 with a return of +206.2%, while the worst single day was Jan 25, 2023 at -75.7%.

Estrella Immunopharma Inc. has an annualized alpha of 5327.20%, beta of 1.58, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 15, 2021.

• This stock participated in 145.24% of S&P 500 Index downside but only -10.24% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ESLAW ranks 53 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Estrella Immunopharma Inc. (ESLAW) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Estrella Immunopharma Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Estrella Immunopharma Inc. was 96.11%, occurring on Jan 25, 2023. The portfolio has not yet recovered.

The current Estrella Immunopharma Inc. drawdown is 86.51%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Estrella Immunopharma Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Estrella Immunopharma Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.